Weekly Teriparatide Administration and Preoperative Anterior Slippage of the Cranial Vertebra Next to Fusion Segment < 2 mm Promote Osseous Union After Posterior Lumbar Interbody Fusion.

Ushirozako H, Hasegawa T, Ebata S, Oba H, Ohba T, Mukaiyama K, Isogai Y, Okada E, Ojima T, Takahashi J, Haro H, Matsuyama Y

Spine1 Mar 2019Cited by 26 (Europe PMC)

PMID30095791DOI10.1097/brs.0000000000002833PepBankPUB-30095791

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

01HumanObservational studyEfficacy outcome
In elderly women after lumbar interbody fusion, teriparatide administration was independently associated with osseous union within 6 months.
In plain wordsIn elderly women after lumbar fusion, teriparatide was linked to greater odds of bone union than no teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAdjusted association with osseous union
Study
n = 66
Comparator
No teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Odds ratio
4.75 ratio
teriparatide association with osseous union
Source sentences
Summary
Multivariate regression analysis showed that teriparatide administration (odds ratio, 4.75; 95% confidence interval: 1.51-14.90; P < 0.01)
4 context sentences(design, population, supporting numbers)
Summary · context
were independently associated with osseous union within 6 months after PLIF.
Summary · context
We analyzed 66 elderly patients with osteoporosis who underwent PLIF from 2011 to 2014 (all women, mean age 71 years, follow-up period ≥6 months).
Summary · context
Patients were randomly allocated to receive either treatment with weekly teriparatide, starting at 1 week postoperatively, or no teriparatide.
Summary · context
Osseous union was assessed by computed tomography at 6 months postoperatively.
Report a problemFND-3009579102

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In elderly women after lumbar interbody fusion, teriparatide exposure was more frequent among those with osseous union than those without union.
In plain wordsIn elderly women after lumbar fusion, teriparatide use was more frequent with bone union than without union.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTeriparatide exposure by osseous union status
Study
n = 66
Comparator
Women without osseous union
Outcome group
Bone and joint · Musculoskeletal
Measurements
Teriparatide exposure
61%
union group
Teriparatide exposure
27%
nonunion group
Source sentences
Summary
Teriparatide was administered in 20 (61%) patients of the union group and in 9 (27%) patients of the nonunion group (P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed 66 elderly patients with osteoporosis who underwent PLIF from 2011 to 2014 (all women, mean age 71 years, follow-up period ≥6 months).
Summary · context
Patients were randomly allocated to receive either treatment with weekly teriparatide, starting at 1 week postoperatively, or no teriparatide.
Summary · context
Osseous union was assessed by computed tomography at 6 months postoperatively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3009579101
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In elderly women after lumbar fusion, femoral neck BMD increased 1.1% with union and decreased 1.3% without union at six months.
In plain wordsAfter lumbar fusion, elderly women with bone union had greater femoral neck bone density changes than women without union.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD change by union status
Study
n = 66
Comparator
Nonunion group
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD change
1.1%
union group at 6 months
Femoral neck BMD change
−1.3%
nonunion group at 6 months
Source sentences
Summary
At 6 months postoperatively, the mean femoral neck bone mineral density significantly increased by 1.1% in the union group and decreased by 1.3% in the nonunion group (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We analyzed 66 elderly patients with osteoporosis who underwent PLIF from 2011 to 2014 (all women, mean age 71 years, follow-up period ≥6 months).
Summary · context
Patients were randomly allocated to receive either treatment with weekly teriparatide, starting at 1 week postoperatively, or no teriparatide.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3009579103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.